IBDEI0I5 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8483,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8483,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,8483,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,8483,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,8484,0)
 ;;=V11.1^^35^485^24
 ;;^UTILITY(U,$J,358.3,8484,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8484,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,8484,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,8484,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,8485,0)
 ;;=V15.89^^35^485^46
 ;;^UTILITY(U,$J,358.3,8485,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8485,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,8485,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,8485,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,8486,0)
 ;;=V11.3^^35^485^25
 ;;^UTILITY(U,$J,358.3,8486,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8486,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,8486,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,8486,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,8487,0)
 ;;=V15.07^^35^485^26
 ;;^UTILITY(U,$J,358.3,8487,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8487,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,8487,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,8487,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,8488,0)
 ;;=V13.4^^35^485^27
 ;;^UTILITY(U,$J,358.3,8488,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8488,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,8488,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,8488,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,8489,0)
 ;;=V12.72^^35^485^31
 ;;^UTILITY(U,$J,358.3,8489,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8489,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,8489,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,8489,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,8490,0)
 ;;=V12.59^^35^485^30
 ;;^UTILITY(U,$J,358.3,8490,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8490,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,8490,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,8490,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,8491,0)
 ;;=V45.81^^35^485^29
 ;;^UTILITY(U,$J,358.3,8491,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8491,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,8491,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,8491,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,8492,0)
 ;;=V15.84^^35^485^28
 ;;^UTILITY(U,$J,358.3,8492,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8492,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,8492,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,8492,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,8493,0)
 ;;=V15.85^^35^485^47
 ;;^UTILITY(U,$J,358.3,8493,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8493,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,8493,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,8493,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,8494,0)
 ;;=V10.72^^35^485^34
 ;;^UTILITY(U,$J,358.3,8494,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8494,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,8494,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,8494,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,8495,0)
 ;;=V15.3^^35^485^35
 ;;^UTILITY(U,$J,358.3,8495,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8495,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,8495,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,8495,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,8496,0)
 ;;=V10.61^^35^485^37
 ;;^UTILITY(U,$J,358.3,8496,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8496,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,8496,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,8496,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;
 ;;$END ROU IBDEI0I5
